10 Best Mid-Cap US Stocks to Buy Now

Page 1 of 3

U.S. mid-cap stocks have attracted significant interest as companies across various sectors capitalize on emerging growth opportunities. Likewise, the stocks have remained resilient in a choppy market amid heightened volatility triggered by monetary policy uncertainty, geopolitical tensions, and economic growth concerns. The S&P Midcap 400 is up by about 10%.

While large-cap stocks continue to dominate market discussions, mid-cap companies offer investors exposure to businesses with significant expansion potential, established operations, and opportunities to gain market share.

Some mid-cap stocks have delivered exceptional returns. Strong earnings, improving business fundamentals, strategic partnerships, and favorable industry trends have helped drive gains in the individual companies, allowing some to outperform the broader market. However, the stocks have entered a more selective phase, like small-cap stocks after a strong first half of the year.

Rising bond yields threaten to put pressure on the equity market. However, analysts at Jefferies, in a post on CNBC, insist small value stocks are poised to weather the storm better than large companies.

10 Best Mid-Cap US Stocks to Buy Now

Photo by AlphaTradeZone on Pexels

“Over a longer period, higher [rates] for longer has been good for small, value, and cyclicals,” small and mid-cap strategist Steven DeSanctis said

Meanwhile, the outlook for U.S. mid-cap stocks is optimistic, with the potential for further gains if economic growth remains resilient and interest rates become more favorable. The stocks could offer investors an attractive balance between the growth potential of small-cap stocks and the relative stability of large-cap companies.

Additionally, mid-cap stocks could continue to attract interest from investors seeking exposure outside large technology companies whose valuations appear to have gotten out of hand. If large-cap stocks become expensive relative to their earnings prospects, investors may look toward smaller businesses with stronger growth potential or more reasonable valuations. Take a look at the stocks Michael Burry is watching amid AI and tech stock concerns.

In this article, we examine the best-performing U.S. mid-cap stocks in 2026, highlighting the companies that have delivered the strongest returns and the key factors behind their performance.

Our Methodology

To create the list of the 10 Best Mid-Cap U.S. Stocks to Buy Now, we used screeners to identify mid-cap stocks with a market cap between $2 billion and $10 billion that have a consensus ‘Strong Buy’ rating among analysts. Next, we focused on US stocks that have gained more than 20% year-to-date and are popular among elite hedge funds in Q2 2026. The list is presented in ascending order of the number of hedge funds that hold stakes in the stocks.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

Best mid-cap US stocks to buy now

10. Krystal Biotech Inc. (NASDAQ:KRYS)

Number of Hedge Fund Holders: 29

Market Cap as of October 30: $9.61 Billion

Year-to-Date Gain as of October 30: 31.44%

Krystal Biotech, Inc. (NASDAQ:KRYS) stands out among the best mid-cap US stocks to buy now, supported by the commercial success of its gene therapy portfolio. Strong sales growth from its flagship treatment, Vyjuvek, and opportunities to expand into additional rare-disease markets have strengthened investor sentiment. The stock has gained approximately 31% in 2026, outperforming the broader mid-cap market. Is the stock still a Buy?

The rally reflects Vyjuvek’s growing commercial success, as it establishes Krystal Biotech, Inc. as a revenue-generating company in the specialized gene therapy market. In the second quarter of 2026, net sales of the treatment increased 24% to $119.2 million, while its gross margin reached 95%.

Cumulative sales since launch have climbed to $965.9 million, demonstrating the company’s ability to commercialize its treatment and generate substantial revenue. Explore the company’s resilient revenue stream.

Beyond Vyjuvek, Krystal Biotech, Inc. has a pipeline of experimental therapies that could provide additional growth opportunities. It includes KB407 for cystic fibrosis and KB803 for corneal complications associated with dystrophic epidermolysis bullosa. As a result, the company has solid growth avenues.

Wall Street analysts have also expressed optimism about the company’s prospects. On October 15, Citi raised its price target of the stock to $416 from $386 and reiterated a Buy rating. The price target increase follows a clinical update on KB113 for treating basal cell carcinomas in patients with Gorlin syndrome. Earlier on September 24, Goldman Sachs resumed coverage of Krystal Biotech, Inc. with a Buy rating.

9. Navan, Inc. (NASDAQ:NAVN)

Number of Hedge Fund Holders: 38

Market Cap as of October 30: $6.93 Billion

Year-to-Date Gain as of October 30: 63.88%

Navan, Inc. (NASDAQ:NAVN) is one of the best mid-cap US stocks to buy now, owing to rising demand for its AI-powered corporate travel and expense management platform. The company has carved a niche in helping businesses manage corporate travel bookings, payments, and expense reporting through an integrated platform.

Rising demand for its solutions fueled strong second-quarter fiscal 2027 results, with revenue increasing 35% year over year to $232.8 million. Gross booking volume also climbed 45% to $3 billion, reflecting growing customer adoption and higher platform usage.

Moreover, Navan, Inc. raised its full-year revenue guidance to a range of $927 million to $933 million, signaling management’s confidence in sustaining its growth momentum. Explore why management hiked guidance.

Artificial intelligence is also emerging as an important growth driver for the company. Navan’s AI-powered travel assistant and automated customer support tools are enhancing the travel experience by helping users manage bookings while allowing businesses to streamline expense management.

The company has also deployed NVIDIA Nemotron 3.5 Super VL to power several of its AI travel agents, further strengthening its automation capabilities. Why did Navan collaborate with Engine?

Strong revenue growth, expanding enterprise adoption, AI-driven automation, and progress toward improved adjusted profitability reinforce Navan, Inc.’s position as a compelling mid-cap stock.

Page 1 of 3